Elon Musk stated in France on Friday that his brain-chip business, Neuralink, plans to implant neural implants in the first human “this year.” Musk, the CEO of Tesla, Twitter, and SpaceX, revealed at the VivaTech event in Paris that Neuralink intends to execute a web casted implantation surgery. Musk, on the other hand, did not disclose specifics about the number of patients or the duration of the research.
The US Food and Drug Administration (FDA) approved Neuralink’s initial human clinical trial last month, which was characterized as a significant milestone for the firm. In the United States, Neuralink is also being investigated for its management of animal trials. Former Neuralink employees have already revealed that the business hurried and mismanaged surgery on monkeys, pigs, and sheep, resulting in the unnecessary death of the animals.
Musk allegedly put pressure on employees to get FDA approval, and the animal experiments were designed to assist the company’s application for human trials
Musk allegedly put pressure on employees to get FDA approval, and the animal experiments were designed to assist the company’s application for human trials. Experts have stated that even if Neuralink proves the device’s safety in people, it might take several years, if not more than a decade, to receive commercial usage certification. Furthermore, other neurotech firms that have already implanted their devices in humans compete with the company. Musk has already missed public announcement deadlines for Neuralink.
Since 2019, he has predicted human trials would begin on at least four occasions, multiple reports have stated. Neuralink, which was formed in 2016, sought FDA approval in early 2022 but was denied due to various safety concerns. These concerns included the gadget’s lithium battery, the potential migration of implant wires within the brain, and the difficulty of securely withdrawing the device without injuring brain tissue. Despite these problems, Neuralink’s stock price has risen dramatically in recent months.
Following a valuation of roughly $2 billion in a private fundraising round two years ago, the company’s value has now risen to around $5 billion based on privately completed stock trades.
